New Peptide Combination Shows Superior Weight Loss to Leading Obesity Drug Duo in Preclinical Study

Ascletis Pharma announced that preclinical data for ASC36_35 FDC, a once-monthly injectable co-formulation of two peptide drug candidates, will be presented in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting in Milan this fall. In a diet-induced obese rat model, the fixed-dose combination produced superior weight loss compared to eloralintide combined with tirzepatide, two of the most closely watched compounds in today's obesity-drug landscape. Jinzi Jason Wu, Ascletis' founder, chairman and CEO, said the data reflect the importance of advancing new treatment options for patients with obesity.

The ASC36_35 fixed-dose combination pairs ASC36, a peptide amylin-receptor agonist, with ASC35, a dual peptide agonist of the GLP-1 and GIP receptors, packaged into a single once-monthly subcutaneous injection. Ascletis describes the co-formulation as a potentially first-in-class candidate because it engages three validated metabolic targets, the amylin receptor, GLP-1R and GIPR, at once. The once-monthly dosing relies on the company's Self-Assembling Lipid Depot formulation, part of its proprietary Ultra-Long-Acting Platform, which is designed to slow-release peptide payloads over weeks rather than days.

Ascletis' announcement lands in the middle of an unusually crowded year for obesity peptide research. A new State of Peptides 2026 report from the Peptide Alliance pegs the broader peptide market at $50 to $60 billion, with GLP-1 and related multi-receptor agonists cited as a primary growth driver, while Ascletis itself has spent 2026 advancing a stack of related programs, including ASC30, an oral small-molecule GLP-1R agonist, and ASC37, a triple GLP-1R/GIPR/GCGR peptide agonist. The pace reflects a broader industry pattern: as tirzepatide and other dual agonists become the benchmark to beat, companies are increasingly pairing peptides that hit different metabolic receptors in a single formulation to chase incremental gains in weight loss.

Preclinical peptide combinations like ASC36_35 are still years away from any pharmacy shelf, and Ascletis' data are limited to an animal model presented at a scientific meeting, not a clinical trial in humans. But the steady drumbeat of new multi-receptor peptide candidates underscores how fast the underlying science is moving, and how much research demand there is for well-characterized amylin, GLP-1 and GIP peptide analogs to study receptor behavior, formulation stability and combination effects. For labs working with these compound classes, that only raises the importance of starting from documented, third-party-verified material. Every peptide Kynetide lists ships with a batch-specific Certificate of Analysis confirming 99%+ HPLC purity, and every product is intended strictly for laboratory research use, not for human or animal administration.

Not yet, and not for some time. The data Ascletis is presenting come from a diet-induced obese rat model, not a human trial, and the findings will be discussed at EASD's Annual Meeting in Milan this fall. Ascletis has already secured FDA IND clearance for related programs, including ASC36 as a standalone injection, but ASC36_35 as a fixed-dose combination remains in earlier-stage development. Any path to approval would still require completing the standard phases of human clinical testing before the combination could reach patients.

It reinforces it. Whether or not multi-receptor combinations like ASC36_35 eventually reach the clinic, the underlying research categories, amylin analogs, GLP-1/GIP dual agonists, and long-acting peptide formulations, are exactly the compound classes labs are studying right now. Kynetide's role isn't to speculate on which pipeline candidate will win; it's to make sure researchers working in this space have documented, third-party-verified starting material. Every peptide we offer ships with a batch-specific Certificate of Analysis confirming 99%+ HPLC purity, and our products are intended strictly for laboratory research, not for human or animal use, dosing, or self-administration.